Trevi Therapeutics (TRVI)

• Market cap: $614M
• 1 day: 1.28%
• 5 days: 4.44%
• 1 month: -0.78%
• 3 months: 62.40%
• 6 months: 104.18%
• Year to date: 45.64%
• 1 year: 139.62%
• 5 years: 120.49%
• 10 years: -19.52%
• Sector: Healthcare
• Industry: Biotechnology

About: Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Employees: 26

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

271% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 7

96% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 24

70% more capital invested

Capital invested by funds: $194M [Q3] → $329M (+$135M) [Q4]

16% more funds holding

Funds holding: 93 [Q3] → 108 (+15) [Q4]

8.84% more ownership

Funds ownership: 80.07% [Q3] → 88.91% (+8.84%) [Q4]

13% less call options, than puts

Call options by funds: $927K | Put options by funds: $1.06M

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12.50 97% upside
• Avg. target: $21 232% upside
• High target: $29 357% upside

6 analyst ratings

• positive: 6 100%
• neutral: 0 0%
• negative: 0 0%

Needham Serge Belanger 43% 1-year accuracy 53 / 123 met price target	278% upside $24	Buy Reiterated	8 Apr 2025
B. Riley Securities Mayank Mamtani 9% 1-year accuracy 2 / 22 met price target	215% upside $20	Buy Reiterated	19 Mar 2025
D. Boral Capital Jason Kolbert 22% 1-year accuracy 81 / 364 met price target	231% upside $21	Buy Maintained	19 Mar 2025
HC Wainwright & Co. Oren Livnat 52% 1-year accuracy 26 / 50 met price target	97% upside $12.50	Buy Reiterated	19 Mar 2025
Oppenheimer Leland Gershell 40% 1-year accuracy 18 / 45 met price target	215% upside $20	Outperform Maintained	11 Mar 2025